Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
The Future Of Inflammation: The Inflammasome And Beyond
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer’s Disease at Discovery Europe 2024
Dr. Bearss will be the Chair of the “Drug Discovery for Neurodegenerative Diseases” session, on May 23.
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI- Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2)
Halia Therapeutics co-founder David J. Bearss Featured in Utah Business
Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
BioTuesdays Features Halia Therapeutics CEO
In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]